Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Pines

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Expert Opinion on Drug Discovery|March 14, 2013
Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginoneMark Pines
World Journal of Gastroenterology|October 31, 2014
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tractMark Pines
Molecules (Basel, Switzerland)|January 9, 2015
Halofuginone - the multifaceted moleculeMark Pines, Itai Spector
Histology and Histopathology|December 1, 2010
Halofuginone and muscular dystrophyMark Pines, Orna Halevy
Journal of Molecular Neuroscience : MN|April 5, 2002
Growth hormone (GH) action in the brain: neural expression of a GH-response geneSteve Harvey, Irina Lavelin, Mark Pines
Bioorganic & Medicinal Chemistry|March 22, 2014
The chemistry and biology of febrifugine and halofuginoneNoel P McLaughlin, Paul Evans, Mark Pines
Nephron. Experimental Nephrology|June 1, 2006
Inhibition of rat renal fibroblast proliferation by halofuginoneNurit Haran, Ludmila Leschinski, Mark Pines, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 19, 2003
Halofuginone to treat fibrosis in chronic graft-versus-host disease and sclerodermaMark Pines, David Snyder, Shai Yarkoni, et al.
Experimental Cell Research|January 12, 2010
Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusionSuzy Roffe, Yosey Hagai, Mark Pines, et al.
Neuromuscular Disorders : NMD|May 27, 2020
Early pathological signs in young dysf<sup>-/-</sup> mice are improved by halofuginoneHila Barzilai-Tutsch, Olga Genin, Mark Pines, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Expert Opinion on Drug Discovery|March 14, 2013
Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginoneMark Pines
World Journal of Gastroenterology|October 31, 2014
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tractMark Pines
Molecules (Basel, Switzerland)|January 9, 2015
Halofuginone - the multifaceted moleculeMark Pines, Itai Spector
Histology and Histopathology|December 1, 2010
Halofuginone and muscular dystrophyMark Pines, Orna Halevy
Journal of Molecular Neuroscience : MN|April 5, 2002
Growth hormone (GH) action in the brain: neural expression of a GH-response geneSteve Harvey, Irina Lavelin, Mark Pines
Bioorganic & Medicinal Chemistry|March 22, 2014
The chemistry and biology of febrifugine and halofuginoneNoel P McLaughlin, Paul Evans, Mark Pines
Nephron. Experimental Nephrology|June 1, 2006
Inhibition of rat renal fibroblast proliferation by halofuginoneNurit Haran, Ludmila Leschinski, Mark Pines, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 19, 2003
Halofuginone to treat fibrosis in chronic graft-versus-host disease and sclerodermaMark Pines, David Snyder, Shai Yarkoni, et al.
Experimental Cell Research|January 12, 2010
Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusionSuzy Roffe, Yosey Hagai, Mark Pines, et al.
Neuromuscular Disorders : NMD|May 27, 2020
Early pathological signs in young dysf<sup>-/-</sup> mice are improved by halofuginoneHila Barzilai-Tutsch, Olga Genin, Mark Pines, et al.
Pageof 6